Evaluation of early-phase [F]-florbetaben PET acquisition in clinical routine cases.

Objectives: In recent years several [F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [F]-florbetaben (FBB) PET compared to [F]-fluorodeoxyglucose (FDG) PET in a clinical setting.